Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer commented on. Cramer noted that the company is “constantly taking share” from its competition, as he remarked: We have the chief maker ...

Eli Lilly and Company (NYSE:LLY) executives highlighted strong 2025 performance, continued demand for its incretin medicines, ...

Hims & Hers has a GLP-1 weight loss pill -- and it's the cheapest one out there.

Eli Lilly and Company (NYSE:LLY) Q4 2025 Earnings Call Transcript February 4, 2026 Eli Lilly and Company beats earnings ...

Historical evidence indicates that abrupt market fluctuations can affect any corporation, regardless of its perceived dominance.

Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit ...

Novo Nordisk and Eli Lilly have been battling head-to-head in an exploding obesity market. They should never have been ...

Eli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's quarterly earnings results, state of the weight-loss ...

The campaign highlights the crossover that Lilly sees between its own 150 years of working toward scientific progress and the ...

Pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) will open a $3.5 billion manufacturing facility in the Lehigh Valley community of Upper Macungie. The development will span about 925,000 square feet ...

Structure Therapeutics has a promising GLP-1 drug that is about to enter phase 3 trials.

The Lehigh Valley plant will be Indianapolis-based Lilly’s first manufacturing facility in Pennsylvania. Construction is ...